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Characterization of intracellular pathways underlying the pleiotropic actions of insulin-like growth factor-I (IGF-I) on brain cells is incomplete.
We analyzed IGF-I signalling on astrocytes through the canonical phosphatidylinositol 3-kinase (PI3K)/Akt pathway and focused on possible
changes in PTEN, a phosphatase that modulates IGF-I signalling by inhibiting Akt activation and, in turn is positively regulated by PI3K. After
exposure of astrocytes to IGF-I, PTENmRNA and protein levels were reduced and its phosphatase activity diminished. Inhibition of PTEN involved
activation of a PI3K/protein kinase C (PKC) pathway that decreased in a proteasome-dependent step the levels of the transcription factor Egr-1, a key
regulator of PTEN levels in astrocytes, causing decreased binding of Egr-1 to the PTENpromoter. Enhancedmitogenesis in PTEN siRNA-transduced
astrocytes after IGF-I suggested that reduced PTEN may be a permissive factor for the mitogenic activity of IGF-I. Subsequent recovery of reduced
PTEN required also activation by IGF-I of PI3K to recruit in this case protein kinase A (PKA)which stimulated Egr-1 levels and, consequently PTEN
synthesis. Because basal levels of PTEN in astrocytes are also governed by PI3K, IGF-I appears to modulate PTEN in astrocytes by redirecting its
homeostasic control through PI3K in a timed fashion.
© 2007 Elsevier B.V. All rights reserved.Keywords: IGF-I; Astrocyte; PI3K; PTEN; PKA; Egr-1; PKC1. Introduction
Insulin-like growth factor I (IGF-I) is a wide-spectrum
neuroactive factor expressed in the central nervous system and
many other tissues [1,2]. In the brain, IGF-I promotes neuro-
protection by modulating all types of brain cell functions in a
distinct fashion [3]. Intriguingly, IGF-I appears to recruit the
same intracellular cascades in its target cells not only in the
brain but elsewhere; these include the canonical phosphatidy-
linositol 3-kinase (PI3K)/AKT and Ras/Mitogen activated
protein kinase (MAPK) pathways [4,5] known to be involved
in the growth and differentiating effects of IGF-I. However, the
actions of IGF-I on its different target cells are quite specific.
For instance, in astrocytes IGF-I exerts proliferative effects [6],
while in neurons it is a potent pro-survival signal [7] and in
oligodendrocytes participates in their differentiation [8]. There-⁎ Corresponding author. Tel.: +34 91 5854723; fax: +34 91 5854754.
E-mail address: torres@cajal.csic.es (I. Torres-Alemán).
0167-4889/$ - see front matter © 2007 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamcr.2007.10.020fore, a better understanding of the molecular pathways under-
lying cell-specific actions of IGF-I on brain cells is required.
Phosphatase and tensin homolog deleted from chromosome 10
(PTEN) is a dual lipid/protein phosphatase [9–11] that dephos-
phorylates phosphatidylinositol 3,4,5-triphosphate (PIP3) and in
this way inhibits the PI3K/AKT kinase pathway [12–14]. Modu-
lation of the expression of this phosphatase is essential in regu-
lating cell viability [15–17], while in the brain PTEN appears to
play a role in neuronal differentiation and in proliferation of
astrocytes [18]. Recently, a positivemodulation of PTENbyPI3K
was reported [19]. Because IGF-I induces activation of the IRS/
PI3K/Akt in target cells, including astrocytes [6], modulation of
PTEN in astrocytes by IGF-I appears likely. We explored this
possibility because while searching for cell-specific actions of
IGF-I on brain cells we found that PTEN mRNA levels were
modulated in forebrain astrocytes but not in cerebellar neurons.
We now show a biphasic regulation of PTEN by IGF-I in
astrocytes through PI3K. This timed modulation involves protein
kinase C (PKC), as a negative regulator, and protein kinase A
804 S. Fernández et al. / Biochimica et Biophysica Acta 1783 (2008) 803–812(PKA), as a positive modulator, converging at the upstream
regulatory transcription factor Early growth response-1 (Egr-1).
2. Materials and methods
2.1. Antibodies and reagents
Culture media, serum and supplements were from Invitrogen (USA). Human
recombinant IGF-I was from GroPep (Australia). Wortmannin, LY294002,
H89, Bisindolylmaleimide IX (Ro813220), PD98059, Cycloheximide and
Ro-32-0432 were from Calbiochem (USA). Forskolin, MG132, the phorbol
ester 12-O-tetradecanoyl phorbol-13-acetate (TPA), and picropodophyllin (P)
were purchased from Sigma (USA). In all cases, drugs were added at the lowest
concentration that produces the maximal effect. Antibodies against N-end PTEN
(sc-9145), AKT (sc-8318), Egr-1 (sc-110), insulin-like growth factor-1 receptor
beta subunit (IGF-IR-β) (C-20, sc-713), and PKA Iα reg (C-14, sc-18800) were
from Santa Cruz (USA). Monoclonal anti-β-actin (clone AC-74, Sigma) was
used to normalize protein load in Western blots. Phosphospecific antibodies
against Phospho-PTEN (Ser380/Thr382/383) and Phospho-AKT (Ser 473) were
from Cell Signalling (USA). Phosphorylated IGF-I receptor from AbCam was
also used. Secondary HRP-anti-mouse, HRP-anti-rabbit and HRP-goat anti-
bodies were from Bio-Rad (USA). Anti-GADPH antibody was purchased from
Affinity Bio Reagents (ABR) (USA).
2.2. Plasmids and reporter constructs
The pGL3-P10 plasmid (kindly provided by E.D. Adamson, the Burnham
Institute) was used to obtain the 1,978-bp PTEN promoter and cloned into a SEAP
reporter vector (Clontech, pPten-SEAP). pCMV-IGF-IR (K1003R) a derivative of
pBS-IGF-IR (K1003R, fromD. LeRoith,Mt. Sinai) inwhich the IGF-IR (K1003R)
is a kinase dead [20]. IGF-I receptor beta-subunit was cloned into a peGFPNI vector
(Clontech). pCDNA3.1 (Invitrogen), pCDNA3-AKTwild type and pCDNA3-AKT
kinase deadwere also used. TheAKTconstructswere provided by S. Pons (Instituto
de Biomedicina). A protein kinase A-α I regulatory subunit kinase dead was kindly
provided by Stanley MacKnight (University of Washington) and cloned into the
pCDNA3.1 expression vector.
2.3. Cell cultures
Astrocyte and neuronal cultures were prepared from postnatal day 3 (P3) rat
telencephalon and P7 rat cerebellum, respectively, as described [21,22]. Astroglial
cultures were grown on Dulbecco's modified Eagle's medium (DMEM) sup-
plemented with 10% fetal calf serum. After 10–15 days astrocytes were seeded in a
12-well plate. Cerebellar granule neurons were grown (2×106 cells/well) on
polystyrene dishes with Neurobasal +B27 (Gibco, USA), glutamine, and 25 mM
KCl. Under these conditions, 95% of the cells are neurons (β3-tubulin-positive).
Cultures were placed in a humidified incubator at 37 °C and 5% CO2 atmosphere.
The day of the experiment, the medium was replaced by Neurobasal plus 25 mM
KCl in neuronal cultures and in astrocytes cultures with serum-free DMEM. After
3 h IGF-I (at the indicated concentrations)was addedwhile inhibitors or other drugs
were given 30min before IGF-I treatment. TheC6 rat glioma and theU373MGand
T98G human glioblastomas were cultured in DMEM.
2.4. Trasient transfections and gene reporter assays
Astrocytes were seeded at 50,000 cells/well in a 12-well culture plate 24 h
before transfection to reach∼70%confluence by the time of transfection. Transient
transfections were performed with 500 ng of each construct with Fugene 6 (Roche
Applied Science) following the manufacturer's instructions. After 16–24 h, the
medium was replaced with serum-free medium and 3 h later treated with 100 nM
IGF-I. 25 μl of medium were used to measure PTEN promoter activity with the
SEAP reporter system (BD Biosciences) using CSPD substrate (Tropix, USA) and
quantified in a luminometer (Berthold Detection Systems, Germany). All samples
were done in triplicate and independent experiments repeated at least four times.
Transfections were normalized by co-transfection with a green fluorescent protein
(peGFPN1) expression vector.2.5. siRNA interference
Three different annealed siRNAs were pre-designed for rat Egr-1 and PTEN
genes (RefSeq Number NM_012551 and NM_031606, respectively) by Ambion.
The siRNAsequences used for Egr-1were 5′GGACTTAAAGGCTCTTAATAtt3′,
5′CCTTTTCTCCTAGGACAATtt3′ and 5′GGACAAGAAAGCAGACAAAtt3′
and oligonucleotides to silence PTEN expression were 5′CCCTTTTGTGAA-
GATCTTGtt3′, 5′GGTTTTTGGATTCAAAGCAtt3′and 5′GGAACAATAT
TGATGATGTtt3′. Annealed siRNAs were dissolved in 250 μl of RNAse free
water at 20mM. siPORTNeoFx transfection reagent (Ambion)was used3:1(v/v) in
OPTI-MEM I reduced serum medium (Gibco). After 15 min at room tempera-
ture theRNA/transfection agent complexeswere IGF-I in panel C dispensed into the
emptywell of a 12-well culture plate. Then, astrocyteswere transferred to the culture
plate containing the RNA/transfection agent at a cell density of 9×104 cells/well.
After gently mixing, cells were incubated for different times as indicated. A positive
control with a validated siRNA targeting rat glyceraldehyde-3-phosphate dehy-
drogenase (GADPH) and a negative control siRNA scrambled sequence that bears
no homology to human, rat or mouse genomes were used in parallel (Ambion).
2.6. Western blots
Western blotting was performed as described previously [22]. Cultures were
washed once with ice-cold PBS and lysed with PIK buffer (150 mMNaCl, 20 mM
Tris HCl pH: 7.4, 1% Nonidet P-40, 1 μg/ml aprotinin, 1 μg/ml leupeptin and
1 mg/ml phenylmethylsulfonyl fluoride). To normalize for protein load, mem-
branes were reblotted (Re-Blot plus mild solution, Chemicon, USA) and incu-
bated with an anti-β-actin antibody. Levels of the protein under study were
expressed relative to protein load in each lane as determined by β-actin content.
Different exposures of each blot were collected to ensure linearity and to match
control levels for quantification. Densitometric analysis was performed using
Molecular Image Program (BioRad). A representative blot is shown from a total
of at least three independent experiments.
2.7. RT-PCR
Total RNA from astrocyte cultures was isolated with TRIzol Reagent
(Invitrogen) and used as template to synthesize cDNA using Mo-MLV reverse
transcriptase (Promega, USA). Relative quantitative RT-PCR was performed using
the QuantumRNA Kit (Ambion, USA) according to the manufacturer's conditions.
PCR was performed with the following primers for PTEN cDNA: 5′ GACAGC-
CATCATCAAAGAGA 3′ and 5′ATCCAGGTGATTCTTTAACAG 3′, and
normalized with the Universal 18S Internal Standard. Samples were loaded into a
1% agarose gel and bands were quantified by densitometric analysis using Analysis
Image Program (BioRad).
2.8. Chromatin Immunoprecipitation (ChiP) assay
A Chromatin Immunoprecipitation Kit (Upstate) was used following the
manufacturer's conditions. Astrocyte cultures (1×106 cells) were crosslinked
after the different treatments with 1% formaldehyde (10 min at 37 °C). The cells
were lysed, nuclear fractions collected and resuspended in SDS lysis buffer.
Chromatin was sonicated and the suspension was precleared with Salmon Sperm
DNA/Protein agarose-50% slurry. Chromatin from 1×106 cells was then
incubated with 3 μg of anti-Egr-1 polyclonal antibody (Santa Cruz) or control
without antibody and rotated overnight at 4 °C. The immune complexes were
precipitated, washed, eluted and cross-links reversed. After treatment with
proteinase K, phenol extraction and ethanol precipitation, immunoprecipitated
chromatin was resuspended in 25 μl of H2O. 5 μl of immunoprecipitate or 50 ng
of total input DNA was used for 25 cycles of PCR amplification with the
following primers specific to rat PTEN promoter: ChiP1 5′GACTCTTTGTG-
CACTGCG3′ and ChiP2 5′CAGCGGCTCAAC TCTCAA3′. PCR reactions
were loaded on a 2% agarose gel and visualized by ethidium bromide staining.
2.9. PTEN lipid phosphatase activity
Phosphate released from substrates was measured with a Malachite Green
Phosphatase Assay (Echelon, USA). After treatments, astrocyte cultures were
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protein were immunoprecipitated with a monoclonal anti-mouse PTEN anti-
body. Lipid phosphatase PTEN activity was measured in 50 μl of PTEN activity
buffer (100 mM Tris–HCl (pH 8.0), 10 mM DTT) containing water-soluble
D(+)-sn-1,2-di-O-octanoylglyceryl, 3-O-phospho-linked-phosphatidylinositol
phosphate (PI(3,4,5)P3). Samples were incubated for 30 min at 22 °C with gentle
shaking before measuring absorbance at 620 nm. Inorganic phosphate release was
quantified by comparison to a standard curve of KH2PO4 in distilled H2O.
2.10. PKC and PKA activity
The PepTag assay (Promega) utilizes a brightly coloured fluorescent peptide
substrate that is highly specific to PKC or PKA kinase, respectively. Phos-
phorylation by the kinase changes the net charge of the substrate from +1 to −1,
thereby allowing the phosphorylated and nonphosphorylated versions of the
substrate to be separated on an agarose (0.8%) gel. The phosphorylated species
migrates towards the positive electrode, while the nonphosphorylated substrate
migrates towards the negative electrode. After treatment, astrocyte cultures
(1×106) were washed once with ice-cold PBS and lysed .Total lysates (10–25 μg
in 10 μl) were incubated with the respective kinase reaction mixture (25 μl)
following the manufacturer's protocol. After adding 80% glycerol (1 μl), the
samples were loaded onto an agarose gel (0.8% in 50 mM Tris–HCl, pH 8.0)Fig. 1. IGF-I modulates PTEN in astrocytes. A, Stimulation of astrocytes with 100 nM
Akt while levels of PTEN were modulated in a biphasic manner. Cells were exposed
between phosphorylated and total IGF-I receptor and Akt, respectively, or total p
B, Changes in PTEN mRNA levels (left) after IGF-I paralleled those in protein leve
Left: representative gels stained with ethidium bromide and quantified (histograms). P
Right: representative western blots of PTEN and quantification histograms using β-ac
lipid phosphatase activity was decreased 6 h after IGF-I and increased 24 h later (nand run at 100 V for 15–30 min. The bands were visualized under UV light.
Immediately after photographing the gel, the negatively charged phosphorylated
bands were excised and heated at 95 °C until melted. The volume was adjusted to
250 μl with water. A hot agarose solution (175 μl) was added to a separate tube
containing 75 μl of gel solubilization solution, 100 μl of glacial acetic acid, and
150 μl of distilled water. Using absorbance reading at 570 nm, the number of
units of kinase activity in each slice of agarose was measured following the
manufacturer's instructions.
2.11. Cell proliferation assay and cell counting
Cell proliferation was measured with a DHL Cell viability kit (Anaspec). This
fluorescence method detects cytoplasmic lactate dehydrogenase (LDH) as an
indicator of cell numbers. Astrocyte cultures were seeded in 48-well culture plates
(1×103cells/well). After 3 h of serum starvation cells were treated with 100 nM
IGF-I, and 40 μl of resazurin (that reacts with endogenous LDH to produce the
reaction) was added per well and incubated for 30 min at 37°C in the dark.
Fluorescence was measured at an excitation/emission wavelength of∼540/590. In
cell counting experiments, cells (9×104 cells) were plated onto 12-well plates and
24 h after siRNA transfection (see above) serum starved and stimulated with IGF-I
or vehicle for the indicated times. Cells were gently washed with PBS, trypsinized,
harvested, and resuspended. Cell number was determined by counting with the aidIGF-I resulted in increased levels of phosphorylation of the IGF-I receptor and
from 0 to 24 h. Numbers below blots: fold changes of control levels of the ratios
rotein load (β-actin levels) for PTEN levels. Representative blots are shown.
ls (right): an early decrease (6 h) followed by an increase at later times (24 h).
TEN cDNA (480 bp) and the internal standard 18S (315 bp) are indicated (n=3).
tin for normalization (n=7). C, In parallel to the changes seen in PTEN levels, its
=3). ⁎pb0.05, ⁎⁎pb0.01, and ⁎⁎⁎pb0.001 vs respective controls.
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in triplicate at least 3 times.
2.12. Statistics
A Student's t-test was used to calculate differences between groups; dif-
ferences were considered significant at pb0.05.3. Results
3.1. IGF-I modulates PTEN in astrocytes
In pilot studies analyzing cell-specific IGF-I signalling on brain
cells, we observed a marked increase in the expression of PTEN
mRNA 24 h after the exposure of forebrain astrocytes to IGF-I
(Supplementary Fig. 1). We confirmed this initial observation byFig. 2. Reduced PTEN levels and IGF-I mitogenesis on astrocytes. A, Reduction of P
while pAKT levels after IGF-I were higher. Non-transfected astrocytes (control), or
changes in protein levels. Western blots were done after 6, 24 and 48 h of IGF-I exposu
normalization with β-actin) are shown. B, Inhibition of PTEN expression after 24 h
Note that cell proliferation was markedly augmented even without IGF-I. Cell grow
(time 0). Control cultures received SSsiRNA. (n=5). ⁎⁎⁎pb0.001 IGF-I+siRNA P
PTEN-transfected cultures was significantly greater than control cultures receiving
siRNA control, (△) SS siRNA control. C, PTEN phosphatase activity was significant
astrocytes. (n=3). D, While normal astrocytes proliferated in response to IGF-I (I) or
picropodophyllin (P) blocked IGF-I activity in normal astrocytes and did not affectdetermining that the transcriptional activity of the PTEN promoter
(p-PTEN) was increased in response to IGF-I. A dose-dependent
stimulatory effect of IGF-I on PTEN promoter activity was
observed up to 1 nM, while the stimulation reached a plateau at
24 h (not shown). Since 100 nM IGF-I produced the highest
effect, we used this dose for subsequent studies to obtain robust
responses to IGF-I. Other neurotrophic factors such as NGF
(50 and 100 ng/ml) did not modify PTEN in astrocytes while
BDNF (50 and 100 ng/ml) produced a prolonged modest, but
significant decrease in the levels of this phosphatase at the lower
dose tested (not shown).
Detailed characterization of the action of IGF-I on PTEN was
then conducted. Exposure of forebrain astrocytes to IGF-I in-
creased phosphoIGF-I receptor/phosphoAKT levels and elicited a
biphasic change in PTEN levels; and initial decrease followed by a
rebound (Fig. 1A). PTEN mRNA levels were affected in parallel;TEN protein levels by siRNA markedly diminished PTEN levels in the cultures
astrocytes transfected with a scramble sequence siRNA (SS) showed no major
re (n=4, representative blots are presented). Fold changes in protein levels (after
of siRNA transfection resulted in significantly enhanced cell growth after IGF-I.
th was expressed as percent of the number of cells at the start of the experiment
TEN vs Control+siRNA PTEN. Although not indicated, cell growth in siRNA
SSsiRNA alone. (■) PTEN siRNA+IGF-I, (□) SSsiRNA+IGF-I, (▲) PTEN
ly lower in the 3 glioma cells lines tested. ⁎⁎pb0.01 and ⁎⁎⁎pb0.001 vs normal
the PKC agonist TPA (TPA), glioma cells did not. The IGF-I receptor antagonist
basal proliferation in the cell lines (n=4). ⁎⁎⁎pb0.001 vs basal levels (B).
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phosphatase activity was similarly affected; decreased after IGF-I
exposure and enhanced at later times (Fig. 1C). However, levels of
phosphorylated PTENdid not parallel these changes, as only at late
times they were reduced (not shown). The modulatory actions of
IGF-I on astrocyte PTEN were mediated through the IGF-I re-
ceptor (IGF-IR) since they were abrogated by transfection of a
dominant negative (DN) IGF-IRmutant (Suppl Fig. 2A,B). On the
contrary, overexpression of the wild type (WT) IGF-IR was suf-
ficient to replicate IGF-I actions on PTEN (Suppl Fig. 2A,B). This
is likely related to the fact that astrocytes in culture produce IGF-I
[23]. Confirming previous gene-screens, the modulatory effect of
IGF-I on PTEN was not observed in neurons. Neurons obtained
from the cerebellum, forebrain or the hypothalamus were exposed
to IGF-I but no change in PTEN levels was found (not shown). On
the contrary, PTENwasmodulated by IGF-I in astrocytes obtained
from other brain regions such as the hippocampus or the cere-
bellum (not shown). The temporal pattern of changes in PTEN
levels depended on sustained IGF-I stimulation. Exposure of the
cells during 2 or 4 h to IGF-I was not enough to decrease PTEN
levels at 6 h (Suppl Fig 2C). Similarly, PTEN levels at 24 h
increased after 24 h of continuous exposure to IGF-I, but not after
shorter exposure times of 6 or 12 h (Suppl Fig. 2C).
To determine the functional significance of the inhibition of
PTEN by IGF-I, we tested the mitogenic activity of IGF-I inFig. 3. Pathways involved in inhibition of PTEN by IGF-I. A, Blockade of PI3K activ
with the modulation at 6 and 24 h produced by IGF-I. B, While in DN-AKT-, but no
activity (pAKT/AKT ratio shown below the AKT blot), the modulatory effects
bisindolylmaleimide (B, 1 μM) to the cultures abrogated early (6 h) inhibition of PT
(100 nM) mimicked early effects of IGF-I on PTEN (right upper panel).Representativ
in previous figures.astrocytes transfected with PTEN siRNA to reduce its levels
(Fig. 2A). As already reported [18], low levels of PTEN alone
were sufficient to stimulate astrocyte proliferation markedly, but
astrocyte proliferation was further increased by IGF-I (Fig. 2B).
As expected, under low PTEN levels pAKT levels remained
elevated after IGF-I, without returning to baseline values
(Fig. 2A). However, in 2 human and 1 rat (C6) glioma cell lines
with greatly reduced PTEN activity (Fig. 2C), IGF-I was not
mitogenic (Fig. 2D). This lack of effect of exogenously added
IGF-I in glioma proliferation was not due to autocrine production
of this growth factor as glioma proliferation was not affected by
picropodophyllin, an antagonist of the IGF-IR (Fig. 2D).
3.2. Pathways involved in PTEN inhibition by IGF-I
We searched for pathways involved in the modulatory effects
of IGF-I on PTEN. Addition of the PI3K inhibitor LY294002 to
astrocytes resulted inmarkedly reduced levels of PTEN (Fig. 3A),
indicating that PI3K activity is required to maintain normal levels
of this phosphatase in astrocytes. IGF-I was unable to rescue the
inhibitory effect of PI3K inhibition, suggesting that PI3K is in
the pathway that IGF-I modulates to regulate PTEN levels. Ano-
ther PI3K inhibitor, wortmannin gave similar results (not shown).
Downstream signalling of PI3K throughAKTwas not involved in
the effect of IGF-I on PTEN, as dominant negative AKT did notity with LY294002 (10 μM) inhibited basal levels of PTEN as well as interfered
t in control-transfected (CMV) astrocytes, IGF-I was not able to stimulate AKT
of IGF-I on PTEN remained unaltered. C, Addition of the PKC inhibitor
EN by IGF-I without affecting late increases (24 h). The PKC stimulator TPA
e blots are shown in all panels. Levels are indicated as fold changes of controls as
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after IGF-I was not involved either because its blockade did not
affected the inhibitory action of IGF-I on PTEN (Suppl Fig. 2D).
Thus, we searched for alternative pathways downstream of PI3K.
We found that the PKC inhibitor bisindolylmaleimide IX (B, 1μM)
specifically abrogated the reduction of PTEN levels after IGF-I
(Fig. 3C). To confirm the involvement of this kinase we treated
cells with the PKC-activating phorbol ester 12-O-tetradecanoyl
phorbol-13-acetate (TPA, 100 nM). TPA mimicked the reduction
of PTEN levels by IGF-I (Fig. 3C) aswell as its proliferative effects
in normal, but not in transformed astrocytes (Fig. 2D). Interestingly,
increased PTEN levels found at later times after IGF-I were not
affected by PKC interference, suggesting that this increase did not
reflect a mere post-inhibitory rebound. Measurement of PKC
activity confirmed that IGF-I activated this kinase at 6 but not at
24 h (Fig. 4A). IGF-I required PI3K to activate PKC because the
PI3K inhibitor LY294002 blocked it (Fig. 4B). To determine
which PKC isoform could be implicated in the modulatory ac-
tions of IGF-I, we exposed astrocytes to the concentration depen-
dent inhibitor of PKCα, β and ɛ, Ro-32-0432 (ID50 of 10 μM,
30μM, and 110μM, respectively). At 10 μM,Ro-32-0432 already
reverted the effects of IGF-I (Fig. 4C), pointing to an involvement
of PKCα in the actions of IGF-I.
We then looked for mechanisms downstream of PKC acti-
vation leading to reduced PTEN levels. In astrocytes treated withFig. 4. IGF-I reduces PTEN through PKC. A, PKC activity is increased in astro
Bisindolylmaleimide IX (B) reduced basal and IGF-I-stimulated PKC activity where
involved in stimulation of PKC by IGF-I as the PI3K inhibitor LY294002 (LY) ab
phosphorylated (+)/non-phosphorylated (−) PKC substrate. Quantitation of the excise
of PKCα (10 nM ), βI (30 nM) and ɛ (110 nM) isoforms reverted the PTEN protein d
histograms are shown (n=3). ⁎⁎⁎pb0.001, ⁎⁎pb0.01 vs respective control groups.the proteasome inhibitor MG132, PTEN protein levels were not
reduced after IGF-I (Fig. 5A). This suggested that proteasome
activity was involved in the inhibitory effects of IGF-I on PTEN.
However, reduced PTEN mRNA after IGF-I (Fig. 1B) suggested
that direct proteasome activity might not be involved. Rather,
reduced PTEN mRNA could be due to decreased PTEN tran-
scription. We therefore examined whether the transcription factor
Early growth response-1 (Egr-1), involved in the response to IGFs
and previously shown to positively modulate PTEN transcription
[24,25] was upstream of the inhibitory action of IGF-I on PTEN.
Indeed, we observed that IGF-I decreased the levels of Egr-1
(Fig. 5B). Furthermore, MG-132 addition to IGF-I-treated astro-
cytes abrogated this effect (Fig. 5C). Collectively, these data
suggest that IGF-I induced degradation of Egr-1 through the
proteasome. Reduced Egr-1 levels diminished the activity of this
transcription factor and consequently, reduced PTEN expression.
To further confirm this possibility, we determined whether de-
creased Egr-1 after IGF-I also depended on PKC activity. We
observed that not only the pan-specific PKC inhibitor bisindo-
lylmaleimide abrogated the effect of IGF-I (Fig. 5D), but also the
isoform specific Ro-32-0432 eliminated the effect of IGF-I
(Fig. 5E) at the same doses seen with PTEN (Fig. 4C). We also
tested whether Egr-1 binding to the p-PTEN was modulated
by IGF-I. As determined with a chromatin immunoprecipitation
(ChIP) assay, reduced levels of Egr-1 protein after IGF-I (Fig. 5B)cytes early after IGF-I addition (6 h) but not after 24 h. The PKC inhibitor
as the PKC agonist TPA mimicked the action of IGF-I at 6 h (n=4). B, PI3K is
rogated the action of IGF-I. Representative agarose gels showing the bands of
d bands is shown in histograms. C, Exposure to Ro-32-0432, a selective inhibitor
ecrease after 6 h of IGF-I already at 10 nM. Representative blots and quantitation
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Finally, we inhibited Egr-1 through siRNA interference in astro-
cytes expressing a p-PTEN reporter vector and found that reduced
Egr-1 resulted in reduced activity of p-PTEN in either the absence
or the presence of IGF-I (Fig. 5G,H; pb0.001 vs SS-transfected
astrocytes), indicating that Egr-1 is required to maintain the acti-
vity of p-PTEN.
3.3. Pathways involved in PTEN recovery after IGF-I
We next searched pathways underlying recovery of PTEN
levels and activity after IGF-I-induced inhibition (Fig. 1), andFig. 5. IGF-I inhibits PTEN by decreasing Egr-1 levels in astrocytes. A, Incubation w
B, Levels of Egr-1 are reduced by IGF-I at 6 h. Densitometric analysis of western blots
(compare bands in lanes 2 and 4). D, Addition of the PKC inhibitor bisindolylmaleim
without affecting late increases (24 h). The PKC stimulator TPA (100 nM) mimicked
0432 reverted the decrease of Egr-1 after 6 h of IGF-I already at 10 nM. F, IGF-I red
immunoprecipitation assays (ChiP). A non-immune control (No Ab) and a non-spec
Detection of the captured PTENGC-rich 113-bp promoter fragment was performed by
disrupts the biphasic regulation of PTEN by IGF-I. Astrocytes were cotransfected w
Accordingly, the activity of the PTEN promoter decreased regardless of the presence o
cotransfected with the respective siRNAs and a PTEN promoter reporter vector. Egr-1
Representative experiments are shown. n=at least 3 independent experiments.found that the PKA inhibitorH89 (1μM), abrogated late increases
in PTEN after IGF-I without affecting the early inhibitory phase
(Fig. 6A). That PKA is involved in this late phase is reinforced
by the observation that the PKA agonist forskolin (2 μg/ml)
reproduced the late action of IGF-I on PTEN (Fig. 6A). Fur-
thermore, PKA kinase activity is activated by IGF-I after 24 h but
not at 6 h (Fig. 6B). Accordingly, astrocytes transfected with a
dominant negative PKA-α1 subunit showed a decreased expres-
sion of PTENafter 24 h of IGF-I (Fig. 6C).We also determined that
activation of PKA through IGF-I required PI3K as LY294002
inhibited it (Fig. 6D).Altogether this data indicated that after IGF-I,
an active PKA is necessary for the recovery of PTEN.ith the proteasome inhibitor MG132 (5 μM) abolished the reduction of PTEN.
is shown in histograms. C, MG132 also blocked the reduction of Egr-1 by IGF-I
ide (B, 1 μM) to the cultures abrogated early (6 h) inhibition of Egr-1 by IGF-I
early effects of IGF-I (blots in the right). E, The isoform specific inhibitor Ro-32-
uces the binding of Egr-1 to the PTEN promoter at 6 h, as shown by chromatin
ific antibody (Input) were used as controls. (L, ladder; C, control and I, IGF-I).
PCR.G, Reduced Egr-1 levels with siRNA reduces PTEN levels in astrocytes and
ith Egr-1 siRNA (30 nM) or a siRNA scramble sequence (SS) as a control. H,
r absence of IGF-I when Egr-1 levels were decreased by siRNA. Astrocytes were
and PTEN levels are shown as fold change after normalization withβ-actin levels.
Fig. 6. Recovery of PTEN after IGF-I depends on PKA and Egr-1. A, Inhibition of PKAwith H89 (1 μM) blocked late but not early effects of IGF-I on Egr-1 and PTEN
(24 and 6 h, respectively). Exposure to forskolin (2 μg/ml, F), a PKA agonist, resulted in stimulation of Egr-1 and PTEN at 24 h, mimicking the action of IGF-I. (n=4).
B, PKA activity is increased in astrocytes after 24 h but not after 6 h of IGF-I. Inhibition with H89 or stimulation with forskolin resulted in expected changes in PKA
activity. C, In the presence of a dominant negative PKA (PKAαI–KD) IGF-I only weakly stimulates Egr-1 and PTEN levels at 24 h. CMV: mock-transfected controls.
Note that levels of PKAαI were increased in transfected cultures while levels of pCREB, that is downstream of PKA activation were reduced. Representative blots are
shown (n=3). D, PI3K is involved in stimulation of PKA by IGF-I as LY294002 (LY) abrogated the action of IGF-I. Representative gels showing the bands of
phosphorylated (+)/non-phosphorylated (−) PKA substrate and quantitation histograms are shown. E, Inhibition of protein synthesis with cycloheximide (CHX, 10 μg/
ml) abrogated stimulation of PTEN by IGF-I at 24 h. F, IGF-I stimulates binding of Egr-1 to the PTEN promoter at 24 h. Note the larger band corresponding to the
PTEN promoter in IGF-I (I)-treated astrocytes. (L, ladder; C, control). A parallel increase in levels of Egr-1 was observed after 24 h of IGF-I. Densitometric analysis of
western blots is shown in histograms (n=3). ⁎⁎⁎pb0.001, ⁎⁎pb0.01 vs respective controls. Representative blots are shown.
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protein synthesis as cycloheximide (CHX) abrogated it (Fig. 6E).
In addition, because PTEN expression depends on Egr-1 levels
(Fig. 5F), we confirmed that Egr-1 levels were increased after 24 h
of IGF-I, and in a PKA-dependent fashion (Fig. 6A,C). Further-
more, with the ChiP assay we observed that in parallel to in-
creased levels of Egr-1, binding of this transcription factor to the
p-PTENwas increased 24 h after addition of IGF-I to the astrocyte
cultures (Fig. 6F).
4. Discussion
IGF-I signalling is associated with a great variety of cellular
functions (reviewed in [26]. However, our understanding of themolecular pathways underlying IGF-I signalling on target cells
is far from complete. The present results point to a novel PI3K-
dependent pathway in astrocytes that comprises timed activa-
tion of PKC and PKA by IGF-I which in turn results in biphasic
modulation of the transcription factor Egr-1 and its downstream
target the phosphatase PTEN. Timed regulation of PTEN was
not found in neurons, which provides a clear example of cell-
specific signalling by IGF-I on brain cells. The fact that IGF-I
(and its mimetic TPA) was not mitogenic in various glioma cell
lines sharing in common low PTEN levels, while in normal
astrocytes the mitogenic response was enhanced under low
PTEN conditions, suggests that the reduction of PTEN through
PI3K/PKC is a permissive, but not a a key step in the mitogenic
actions of IGF-I. Conversely, the late increase in PTEN through
Fig. 7. Homeostatic regulation of PTEN by PI3K in astrocytes is modulated by IGF-I. In the steady state, there is a reciprocal regulation of PTEN and PI3K (inset).
Upon activation of the IGF-I receptor, the PI3K/Akt pathway is activated to enhance cell proliferation. However, as shown now by our results, IGF-I activation of PI3K
in astrocytes also leads to timed activation of PKC and PKA. 1) initial activation of PKC and reduction of Egr-1 levels (probably by directing its proteasome
degradation through an as yet unknown process) that are crucial to maintain PTEN levels in the cell, and consequently PTEN levels decrease; and 2) delayed activation
of PKA that results in enhanced levels of Egr-1 (probably through enhanced transcriptional activity induced by PKA-stimulated CREB) that eventually restores PTEN
levels. Dotted pathways indicate the need for further analysis because additional unknown steps are likely involved. While the mechanism involved in timed activation
of PKC and PKA by PI3K remains to be established it is probably related to relative levels of PI3K activity.
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tion in astrocytes with no relation to the mitogenic effects of
IGF-I. Indeed, overexpression of PTEN in wild type astrocytes
did not modify the mitogenic activity of IGF-I (not shown). This
is in line with the proposal that PTEN is a constitutively active
phosphatase subject to negative regulation [27]. At any rate, and
as recently outlined [28], it is difficult to assign a specific phy-
siological significance for PTEN regulation and further work in
this regard is warranted.
However, these observations allow to start delineating the
existence of a complex network between IGF-I and PTEN through
PI3K (Fig. 7), and suggest that the regulation of PTEN activity not
only includes reversible postraslational modifications such as
phosphorylation or oxidation but may also include the regulation
of its cellular levels. The latter seems to involve the growth factor-
sensitive transcription factor Egr-1, which has been shown pre-
viously to be involved in downstream signalling by IGFs
[25,29,30] and to be upstream of PTEN [25]. This is confirmed
by the present findings showing that the levels of Egr-1 are a
critical factor in regulating PTEN synthesis in astrocytes. Reduced
levels of Egr-1 after IGF-I were accompanied by decreased
binding of Egr-1 to p-PTEN and lower levels of PTEN mRNA.
Inhibition of Egr-1 by IGF-I was mediated by PI3K-dependent
activation of PKC-previously shown to have either inhibitory or
stimulatory effects on this transcription factor [31,32]. Activation
of PKC by IGF-I led to enhanced degradation of Egr-1 by the
proteasome pathway as the inhibitory drug MG132 abrogated the
decrease in Egr-1/PTEN after IGF-I. However, the link between
PKC activation and Egr-1 degradation requires further analysis.
Conversely, recovery of PTEN after IGF-I includes activation in a
PI3K-dependent fashion of PKA, which in turn results in in-
creased Egr-1, greater Egr-1 binding to the PTEN promoter and
enhanced PTENmRNA and protein levels. Indeed, the activity of
the p-PTEN is regulated by Egr-1 levels. That recovery of PTEN
levels is through de novo protein synthesis is reinforced by the
observation that cycloheximide blocks it. Significantly, the Egr-1gene promoter has cAMP-sensitive consensus sites [33], and our
preliminary data show that activation of the downstream transcrip-
tion factor CREB may be involved in PKA regulation of Egr-1.
Therefore, increased transcriptional activity of the Egr-1 gene in
response to PKA may drive recovery of PTEN levels.
While the existence of additional intermediate steps along
this intricate pathway needs to be determined, in particular the
cellular mechanism supporting delayed activation by IGF-I of
PKA through PI3K, these findings provide a physiological
context for the recently described regulatory action of PI3K on
PTEN [19]. Our observations also provide a deeper insight into
the role of PI3K on PTEN regulation showing that it can be
either negative (through PKC) or positive (through PKA).
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